NCT05551689

Brief Summary

The study is a randomized clinical trial to evaluate the efficacy on treatment adherence, performance and usability of the mobile health solution FOCUS ADHD, in combination with a discount application in the purchase of psychostimulant medication by adult patients with ADHD

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
73

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 21, 2021

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

September 16, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 23, 2022

Completed
7 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2022

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 30, 2023

Completed
Last Updated

May 16, 2024

Status Verified

May 1, 2024

Enrollment Period

1.4 years

First QC Date

September 16, 2022

Last Update Submit

May 14, 2024

Conditions

Keywords

mhealthapp

Outcome Measures

Primary Outcomes (2)

  • Adherence to pharmacological treatment of ADHD

    Treatment adherence will be calculated using the medication possession ratio (MPR) as the total number of days provided for the medication, divided by the number of days between the first and last dispensation; An 80% MPR will be used as the cut-off point between adherence and non-adherence. For the group that includes the discount on medication it will be evaluated the frequency of registration in the medication intake in the FOCUS ADHD application database as eligibility criteria for the discount concession.

    Treatment adherence will be monitored through weekly telephone contact. Week 1 to 12.

  • ADHD Knowledge Change

    This is a questionnaire created in order to identify participants awareness about ADHD and the degree of information/misinformation about the disease and its management.

    The participants knowledge on ADHD should be carried out in two moments to evaluate the change or not of participants ADHD knowledge. At the beginning of the study on the baseline assessment and at the end of the follow-up period (Week 12)

Secondary Outcomes (3)

  • FOCUS ADHD Adoption

    End of the follow up period (Week 12)

  • FOCUS ADHD Retention

    Weekly assessments Week 1 to Week 12

  • FOCUS ADHD Usability

    End of the follow up period (Week 12)

Study Arms (3)

ADHD monitoring as usual

ACTIVE COMPARATOR

ADHD patient monitoring as usual based on psychostimulant prescription and follow up

Drug: Psychostimulant

FOCUS ADHD

EXPERIMENTAL

ADHD patient monitoring as usual based on psychostimulant prescription and follow up plus the indication to use the FOCUS ADHD app as a treatment monitoring tool

Drug: PsychostimulantDevice: FOCUS ADHD App

FOCUS ADHD and the elegibility for discount concession on treatment purchase

EXPERIMENTAL

ADHD patient monitoring as usual based on psychostimulant prescription and follow up plus the indication to use the FOCUS ADHD app as a treatment monitoring tool. In this arm patients are also eligible for a discount of at least 25% of the drug cost (after the first month of treatment) if they register and maintain at least 80% of their treatment adherence on the FOCUS ADHD app. The discount is granted after week 4 until the end of the follow up period.

Drug: PsychostimulantDevice: FOCUS ADHD App

Interventions

All enrolled patients should be receiving ADHD pharmacological treatment (psychostimulants)

Also known as: Methilphenidate, Lisdexamfetamine
ADHD monitoring as usualFOCUS ADHDFOCUS ADHD and the elegibility for discount concession on treatment purchase

FOCUS ADHD is a mobile health application to support ADHD treatment adherence, monitoring and psychoeducation. The App was developed by the Attention Deficit Hyperactivity Disorder Program (ProDAH) of the Hospital de Clínicas de Porto Alegre (HCPA) and the Federal University of Rio Grande do Sul (UFRGS)

Also known as: mhealth app
FOCUS ADHDFOCUS ADHD and the elegibility for discount concession on treatment purchase

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Subject is willing and able to comply with all requirements of the study;
  • Subject is able to provide written consent;
  • Subject has a diagnosis of ADHD according to DSM-5;
  • age 45 \< 18 years;
  • own smartphone;
  • ASRS score at diagnosis ≥ 24
  • Subject accepts usage of pharmacological treatment for ADHD during the study;

You may not qualify if:

  • patients with any unstable or chronic clinical disease without adequate treatment, notified arterial hypertension, heart, kidney or liver diseases;
  • presence of unstable psychiatric comorbidities requiring immediate treatment such as depression at risk of suicide or substance abuse/dependence, including anxiety and bipolar disorder. current or past history of psychosis;
  • Patients with incomplete high school

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital de Clínicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, 90035-007, Brazil

Location

Related Publications (1)

  • Carvalho LR, Haas LM, Zeni G, Victor MM, Techele SP, Marrone Castanho J, Meneghetti Coimbra I, de Freitas de Sousa A, Ceretta N, Garrudo A, Grevet EH, Rohde LA. Evaluation of the effectiveness of the FOCUS ADHD App in monitoring adults with attention-deficit/hyperactivity disorder. Eur Psychiatry. 2023 Jun 21;66(1):e53. doi: 10.1192/j.eurpsy.2023.2422.

Related Links

MeSH Terms

Conditions

Attention Deficit Disorder with HyperactivityAlzheimer Disease

Interventions

Lisdexamfetamine Dimesylate

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental DisordersDementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive Disorders

Intervention Hierarchy (Ancestors)

DextroamphetamineAmphetamineAmphetaminesPhenethylaminesEthylaminesAminesOrganic Chemicals

Study Officials

  • Luis Augusto P Rohde, MD-PhD

    Hospital das Clínicas de Porto Alegre

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, OUTCOMES ASSESSOR
Masking Details
Participants are randomized by an independent assistant.
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: randomized clinical trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 16, 2022

First Posted

September 23, 2022

Study Start

May 21, 2021

Primary Completion

September 30, 2022

Study Completion

March 30, 2023

Last Updated

May 16, 2024

Record last verified: 2024-05

Locations